1 / 55

CTOS 14th Annual Meeting London, 13-15 November 2008 ALTERNATIVE CLINICAL APPROACH

CTOS 14th Annual Meeting London, 13-15 November 2008 ALTERNATIVE CLINICAL APPROACH IN AGGRESSIVE FIBROMATOSIS: WAIT & SEE FRONTLINE POLICY. A MULTI-INSTITUTIONAL RETROSPECTIVE REVIEW. Marco Fiore and Sylvie Bonvalot.  -Catenin. Primary AF 5-yrs DFS 81% 10-yrs DFS 76%.

natane
Télécharger la présentation

CTOS 14th Annual Meeting London, 13-15 November 2008 ALTERNATIVE CLINICAL APPROACH

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CTOS 14th Annual Meeting London, 13-15 November 2008 ALTERNATIVE CLINICAL APPROACH IN AGGRESSIVE FIBROMATOSIS: WAIT & SEE FRONTLINE POLICY. A MULTI-INSTITUTIONAL RETROSPECTIVE REVIEW. Marco Fiore and Sylvie Bonvalot

  2. -Catenin

  3. Primary AF 5-yrs DFS 81% 10-yrs DFS 76%

  4. Background

  5. Objective

  6. Evaluate the PFS of AF primarily observed (no surgery, no radiation, no medical treatments) on a large series of patients coming from two major referral institutions Correlate PFS with known clinical prognostic factors

  7. Patients and Methods

  8. Aggressive Fibromatosis1995-2008 N° pts. NO SURGERY 142 Primary 74 52.1% Recurrent 68 47.9% Female 99 69.7% Male 43 30.3% Age 15-25 yrs 35 24.6% 26-45 yrs 75 52.8% >45 yrs 32 22.5% Gardner Yes 6 4.2% No / NA 136 95.8% Recent Pregnancy Yes 23 23.2% No 44 44.4% NA 32 32.3%

  9. na >100 <50 50 -100 Distribution by Site and Size Intrabdominal Abdominal Wall H&N Thoracic Wall Extremity Trunk

  10. 73% 43% Treatment at Referral

  11. Treatment at Referral

  12. Which definition of PD ? • IGR: increase in size of 25% of the target lesion in comparison with baseline. • INT: any increase in size at MRI, and/or worsening of symptoms in comparison with baseline.

  13. Results

  14. Progression-free Survival (Median follow-up 32.5 mos)

  15. PFS – Primary AF Any Tx W&S

  16. PFS – Recurrent AF Any Tx W&S

  17. Trunk > > Abd. Wall Extremity > > 100 mm < 50 mm Cox Model (Hazard Ratio)

  18. Discussion

  19. W&S: size increase at PD ratio months

  20. W&S: size decrease at spontaneous regression ratio months

  21. W&S: local control after PD 6 / 19 pts Median TTP 5.3 mos Median size 105 mm Local relapse none 10 / 19 pts Median TTP 11.1 mos Median size 66 mm Local relapse 2 / 10

  22. … and what about RT?

  23. Soft tissue necrosis; Fracture; Edema; Fibrosis; Neuropathy; Limb shortening; Second malignancy Local control, 5yrs = 75% Surgery + RT vs RT alone, p = 0.21

  24. ♀♂ Site W&S / Tx Primary / Recurrent Size Age

  25. … Next step?? Molecular Prognosticators Primary disease, W&S

  26. Conclusion

  27. 50.0% Avoid any treatment 63.0% Avoid Surgery

  28. It would be useful to identify upfront those who will progress… (molecular analysis??) • Even in the absence of clinical prognosticators, Wait & See approach revealed to be a good tool to tailor the best treatment strategy

  29. … marco.fiore@istitutotumori.mi.it

  30. Distribution by site Site Extremities / Girdles 65 45.8% Abdominal wall 33 23.2% Thoracic wall 13 9.2% Trunk 9 6.3% H&N 7 4.9% Intrabdominal / Pelvic 15 10.6% Size < 50 mm 54 38.0% 51-100 mm 55 38.7% > 100 mm 21 14.8% NA 12 8.5% Monofocal 124 87.3% Multifocal 18 12.7%

  31. AF - Treatment at referral N° pts. NO SURGERY 142 100.0% Wait & See 83 58.5% Any Medical Tx 59 41.5% Chemotherapy 2847.4% Hormonal (anti-E) 2033.9% NSAIDs 23.4% Imatinib 11.7% ILP 35.1% Multiple 58.8%

  32. Primary AF: W&S approach All Primary 74 39 52.7% 35 47.3% 58 78.4% 16 21.6% 10 13.5% 49 66.2% 15 20.3% N° pts. W&S 54 IGR 34 63.0% INT 20 37.0% Female 44 81.5% Male 10 18.5% Age 15-25 yrs 4 7.4% 26-45 yrs 38 70.4% >45 yrs 12 22.2%

  33. Primary AF: W&S approach All Primary 74 20 27.0% 28 37.8% 9 10.8% 4 5.4% 3 4.1% 10 13.5% 70 94.6% 4 5.4% N° pts. W&S 54 Site Extr. / Girdles 12 22.2% Abdominal wall 28 51.9% Thoracic wall 7 13.0% Trunk 1 1.9% H&N 1 1.9% Intrabd. / Pelvic 5 9.1% Monofocal 51 94.4% Multifocal 3 5.6%

  34. Primary AF: W&S approach All Primary 74 32 43.2% 28 37.8% 10 13.5% 4 5.4% 3 4.1% 71 95.9% 17 23.0% 31 41.9% 26 35.1% N° pts. W&S 54 Size < 50 mm 29 53.7% 51-100 mm 21 38.9% > 100 mm 2 3.7% NA 2 3.7% Gardner Yes 3 5.5% No / NA 51 94.5% Pregnancy Yes 16 29.6% No 27 50.0% NA 11 20.4%

  35. Cox Model

  36. W&S: treatment at PD

  37. W&S: local control after surgery at PD N° pts. SURGERY after PD 6 / 19 IGR 5 INT 1 Median tumor size at PD (mm) 105 Median TTP 5.3 (range 1.3 – 46.9) Local relapse none Median FU after PD 12.3 (range 0.8 - 34.8)

  38. W&S: local control after Tx at PD N° pts. Medical Tx after PD 10 / 19 IGR 7 INT 3 Median tumor size at PD (mm) 66 Median TTP 11.1 (range 4.3 – 27.8) Further PD 2 / 10 Median FU after initial PD 7.9 (range 0.0 - 74.4)

More Related